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Abstract. The efficacy and the tolerance of milnacipran 
(100 rag/day), a second generation antidepressant which 
equipotently inhibits both noradrenaline and serotonin 
reuptake, was compared to fluoxetine (20 mg/day), a selec- 
tive serotonin reuptake inhibitor, in two parallel groups 
of, respectively, 97 and 93 major depressive outpatients. 
The duration of the study was 6 weeks, with assessments 
every 2 weeks by means of the Montgomery and Asberg 
depression scale (MADRS), the Hamilton depression 
scale, the clinical global impressions (CGI), and a checklist 
of symptoms and side-effects. Results showed significant 
superiority of fluoxetine over milnacipran on most rating 
instruments: MADRS (P = 0.01) including five individual 
items, Hamilton depression scale (P = 0.002) including 
ten individual items, CGI of severity (P = 0.01) and thera- 
peutical index (P = 0.002). On visual analogue scales as- 
sessing the clinical profile of the compounds, fluoxetine 
was rated as exhibiting more psychostimulating activity 
than milnacipran (P = 0.0008). The tolerance of the two 
antidepressants was very similar, with the exception of 
symptoms of dizziness which were more frequently re- 
ported with milnacipran (P = 0.01). These differences in 
efficacy favoring fluoxetine could result from the selection 
of a dose of milnacipran below the optimal therapeutic 
dose for this type of psychiatric patients or to the adminis- 
tration of the compounds in single daily intakes, whereas 
milnacipran possesses a plasma elimination half-life of 
only 7 h. 
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The classical biochemical hypothesis of major depression 
posits a functional deficit in noradrenergic and/or sero- 
tonergic central neurotransmission (Van Praag 1980a, b). 
Based on this theory, an antidepressant acting on both 
noradrenergic and serotonergic systems could exhibit 
a broader spectrum of efficacy than an antidepressant 
acting on a sole system (Van Praag 1984). Milnacipran 
(1-phenyl- 1-diethyl-amino-carbonyl-2-amino-methylcyc- 
lopropane hydrochloride), a racemic drug, is a new antide- 
pressant selected for its equipotent inhibition of 
noradrenaline and serotonin uptake and its lack of effect at 
any postsynaptic receptor (Motet et al. 1985). Its antide- 
pressant efficacy has already been established as superior to 
placebo (Macher et al. 1989) and equivalent to reference 
tricyclics, particularly amitriptyline (Ansseau et al. 
1989a, b) and clomipramine (Clerc et al. 1990). In all com- 
parative studies, the tolerance of milnacipran was signifi- 
cantly better than tricyclics (Ansseau et al. 1989a, b; Clerc et 
al. 1990). Fluoxetine is a selective serotonin reuptake inhibi- 
tor antidepressant exhibiting efficacy similar to reference 
tricyclics but less anticholinergic side-effects (Benfield et al. 
1986). Therefore, the purpose of the present study was to test 
if milnacipran, acting on both noradrenergie and serotoner- 
gic reuptake mechanisms, could exhibit a different spec- 
trum of activity than fluoxetine, acting solely on serotonin 
reuptake processes. In addition, such comparative data 
involving "second generation" antidepressants are clearly 
needed in order to better define their particular profiles in 
terms of efficacy and tolerance (Benfield and Ward 1986). 
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Subjects and methods 
Design of the study. The study was performed between February 
1990 and October 1991 in 16 Belgian centres used to collaboration 
and exhibiting excellent reliability in clinical rating (see affiliations). 
The trial used a double-blind design with two parallel groups of 
patients randomly assigned to milnacipran 100 mg/day or fluoxetine 
20 rag/day. All treatments were administered as single evening in- 
takes. The active period was preceded by a wash-out period of 4-7 
days on placebo. 
Somatic treatments could be pursued throughout the study 
period, except antiarrhythmic drugs, digitalis drugs, alpha-blocking 
antihypertensive drugs and anorexigens which had to be discontinu- 
ed at least 1 week before the study and beta-blockers which had to 
be used at a stable dose for at least 2 months before the study. The 
association of psychotropic drugs was excluded throughout the 
study period, except for the occasional intake of low dose lorazepam 
as anxiolytic and/or hypnotic. The duration of the study was 
6 weeks, with assessments every 2 weeks. Compliance was ensured 
by drug count; plasma levels were not determined. The trial was 
monitored according to all principles of European and US "good 
clinical practice" (Minist6re des Affaires Sociales et de l'Emploi 1987; 
Mathieu 1990). 
Subjects. A total of 190 outpatients were included in the study: 97 in 
the milnacipran group and 93 in the fluoxetine group. Patients were 
47 males and 143 females, aged from 19 to 68 years, with a mean age 
(SD) of 44.9 (11.2) years. All subjects were depressive outpatients 
who fulfilled DSM-III-R criteria for a major depressive episode 
(American Psychiatric Association 1987) and had a score of at least 
25 on the Montgomery and Asberg Depression Rating Scale 
(MADRS) (Montgomery and Asberg 1979), a score of at least 4 for 
the severity of illness as defined by the clinical global impressions 
(CGI) (Guy 1976), and a score on the Raskin scale for depression 
higher than the score on the Covi scale for anxiety (Raskin et al. 
1967; Covi et al. 1979). Initial scores ranged from 25 to 47 with 
a mean (SD) of 33.6 (4.7) on the MADRS and from 17 to 49 with 
a mean (SD) of 31.5 (5.9) on the 24-item Hamilton depression scale 
(Hamilton 1960). 
Patients presenting serious or uncontrolled medical illness (renal, 
hepatic, respiratory and cardiac failure) were excluded from the 
study. Moreover, patients exhibiting major anxiety, agitation, or 
suicide risk, resistance during the current episode to at least two 
antidepressants prescribed at an effective dose during at least 
3 weeks, substance abuse or dependence were also excluded, as well 
as patients taking lithium, a monoamine oxidase antidepressant, or 
a long acting neuroleptic during the previous month or requiring the 
Table 1. Demographic and clinical characteristics of the sample 
Milnacipran group Fluoxetine group F ?~2 p 
(n = 97) (n = 93) 
Age in years (SD) 44.8 (11.2) 45.0 (12.3) 0.03 
Gender (M/F) (%) 26/74 24/76 0,11 
Weight in kg (SD) 67.3 (13.1) 67.6 (14.4) 0.02 
Previous depressive episodes (SD) 1.53 (2.02) 2.45 (2.69) 6.95 
Time since first onset in wks (%) 310.9 (406.9) 388.4 (427.9) 1.63 
DSM-III-R characteristics of episode (%) 
mild 2.1 0 
moderate 55.7 52.2 
severe 42.3 47.1 0.11" 
chronic 14.4 18.3 0.51 
melancholic 76.3 82.8 1.23 
bipolar (296.5x) 7.2 6.6 
isolated episode (296.2x) 43.3 32.9 
recurrent (296.3x) 49.5 60.4 2.36 
seasonal pattern 4.1 6.4 b 
Duration of episode in wks (%) 30.8 (88.9) 26.1 (48.7) 0.20 
Previous treatments (%) 
antidepressants 32.0 29.0 0.19 
anxiolytics 61.9 64.1 0.11 
DSM-II1-R personality disorders (%) 
paranoid (301.60) 1.0 2.1 b 
schizoid (301.20) 2.1 2.1 b 
schizotypal (301.22) 1.0 2.1 b 
borderline (301.83) 2.1 3.2 b 
histrionic (301.50) 13.4 9.7 0.64 
narcissistic (301.81) 5.1 2.1 b 
avoidant (301.82) 2.1 1.1 b 
dependent (301.60) 12.4 20A 2.26 
compulsive (301.40) 5.1 4.3 b 
passive-aggressive (301.84) 13.4 3.2 b 
Baseline ratinos (SD) 
MADRS 33.4 (4.7) 33.8 (4.7) 0.38 
Hamilton depression scale 30.6 (5.7) 32.4 (6.2) 4.28 
Raskin depression scale 11.0 (1.3) 11.3 (1.3) 2.44 
Covi anxiety scale 7.2 (1.6) 7.6 (1.8) 2.22 
CGI-severity 4.3 (0.6) 4.4 (0.7) 0.76 
Visual analogue scales (ram) 
* depressed mood 72.9 (13.1) 77.2 (10.3) 6.41 
* retardation 51.7 (26.6) 56.7 (24.4) 1.82 
* anxiety 48.6 (20.5) 52.7 (20.9) 1.89 

































" Contingency coefficient; 
b Fisher's exact test 
Assessments. Assessments were performed by means of the 
MADRS, the 24-item Hamilton depression scale, the CGI, and 
a checklist of symptoms and side-effects previously described which 
comprises specific items as well as reserve items related to behavior, 
central nervous system, autonomic nervous system and miscella- 
neous rated as 0 (none), 1 (mild), 2 (moderate) and 3(severe) (see 
Table 3) (Ansseau et al. 1989b, 1991). An open spontaneous notifica- 
tion of adverse events was also used. Moreover, the syndromic 
profile of each patient at inclusion was rated according to four 
100-mm visual analogue scales assessing depressed mood, 
psychomotor retardation, anxiety, and insomnia, and the clinical 
profile of the antidepressant of the end of the study was evaluated 
according to seven 100-mm visual analogue scales assessing specifi- 
cally the antidepressant, psychostimulating, anxiolytic, anticholiner- 
gic, sedative, hypotensive and digestive effects. These parameters 
were selected form a "star" model designed to compare the clinical 
characteristics of individual antidepressants (Ansseau et al. 1985). 
Weight was recorded and laboratory tests, including hepatic and 
renal balance-sheets, were carried out before inclusion and at the 
end of the treatment period. 
Data analysis. Initially, the homogeneity of the two treatment 
groups was controlled, using one-way analysis of variance 
(ANOVA) or Chi-square statistics, the Fisher exact test or the 
contingency coefficient. All changes over time in ratings were as- 
sessed by multivariate ANOVAs with repeated measures using the 
intent to treat sample. An endpoint analysis was also performed but 
since the conclusions were similar, they are not reported in this 
paper. The levels of side-effects were compared between the two 
groups using Chi-square statistics, exact Fisher test, or contingency 
coefficients. All statistical procedures used a SAS package. 
R e s u l t s  
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Dropouts 
A to ta l  of 41 pa t ien ts  (21.6%) d id  no t  comple te  the 6-week 
study: 23 (23.7%) in the mi lnac ip ran  g roup  and  18 (19.3%) 
in the f luoxet ine g roup  (Chi 2 = 0.53, df = 1, P = NS). The  
d is t r ibu t ions  of the reasons  for d r o p o u t s  were inefficacy 
(n = 7), adverse  event (n = 4), inefficacy and  adverse  
events (n = 2), in tercurrent  illness (n = 1), and  lost  to 
fo l low-up (n = 9) in the mi lnac ip ran  group  and  inefficacy 
(n = 4), adverse  events (n = 6), inefficacy and adverse  
events (n = 1), improvemen t  (n = 2), in tercurrent  illness 
(n = 1), and  lost  to fo l low-up (n = 4) in the f luoxetine 
group,  ind ica t ing  signif icantly more  d ropou t s  for ineffic- 
acy and  lost  to fo l low-up in the  mi lnac ip ran  group  (con- 
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MADRS. The changes over t ime on the M A D R S  in the two 
groups are displayed in Fig. 1. F luoxet ine  exhibited signifi- 
cant ly better  ant idepressant  efficacy than  mi lnac ipran  
(F = 6.08, df= 1,149, P = 0.01). Five items showed bet ter  
improvement  with fluoxetine as compared  to milnacipran:  
apparen t  sadness (P = 0.002), expressed sadness (P = 0.03), 
inner tension (P = 0.02), decrease in sleep (P = 0.007) and 
pessimistic thoughts  (P = 0.04). The percentages of treat-  
ment  responders,  as defined by  an improvement  of at  least 
50% from baseline scores, were 4.7% after 2 weeks, 22.5% 
after 4 weeks and 40.0% after 6 weeks in the mi lnac ipran  
group and, respectively, 15.0%, 32.9% and 61.3% in the 
fluoxetine group,  showing significantly more  responders  
with fluoxetine after 2 (P = 0.03) and 6 weeks (P = 0.009). 
Hamilton depression scale. The changes  over  t ime on the 
H a m i l t o n  depress ion scale in the two t r ea tmen t  g roups  
are  presented  in Fig. 2. F luoxe t ine  exhibi ted  a significantly 
1 5  < 
lO m " " 
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current intake of a neuroleptic or an anxiolytic or hypnotic drug 
other than lorazepam at low dose. 
The main demographic and clinical characteristics of the pa- 
tients are presented in Table 1. All data were comparable in the two 
treatment groups, except the number of previous depressive episodes 
and the baseline scores on the Hamilton depression scale and the 
visual analogue scale of depressed mood which were higher in the 
fluoxetine group, and the number of passive-aggressive personalities 
which was higher in the milnacipran group. The number of patients 
needed in each group was determined on the basis of expected 
differences of 20-30% on one or several parameters of activity and 
tolerance using tables comparing several means for two treatment 
groups with an alpha risk = 1% and a beta risk = 5% (Schwartz 
1970). Finally, the protocol was approved by the Ethical Committee 
of the University of Liege Medical School, and patients were fully 
informed of the purpose of the study and gave their consent. 
Time (weeks )  
Fig. 1. Changes over time in mean scores ( + SD) on the MADRS 
among patients treated by milnacipran 100 mg/day or fluoxetine 
20 mg/day 
0 
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Time (weeks)  
Fig. 2. Changes over time in mean scores ( + SD) on the Hamilton 
depression scale (HAM-D) among patients treated by milnacipran 
100 mg/day or fluoxetine 20 mg/day 
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better antidepressant effect than milnacipran (F = 10.02, 
df= 1,149, P = 0.002). Ten items exhibited a better im- 
provement with fluoxetine as compared to milnacipran: 
depressed mood (P = 0.01), middle insomnia (P = 0.03), 
retardation (P - 0.03), psychic anxiety (P = 0.02), somatic 
anxiety (P = 0.03), gastrointestinal symptoms (P = 0.04) 
genital symptoms (P = 0.001), helplessness (P = 0.04), 
hopelessness (P = 0.03) and worthlessness (P = 0.03). 
CGI. The changes over time on the CGI in the two 
treatment groups are presented in Table 2. The CGI 
related to the severity of illness exhibited a significantly 
better outcome with fluoxetine as compared to milnacip- 
ran (F = 6.71, df= 1,150, P = 0.01). The global improve- 
ment did not exhibit a significant difference in outcome 
between the treatment groups ( F =  3.20, df= 1.150, 
P = 0.08). In contrast, the efficacy index showed a better 
result with fluoxetine as compared to milnacipran 
(F = 9.67, df= 1,150, P = 0.002). 
Visual analogue scales. The mean ratings of the clinical 
profile of the antidepressant on visual analogue scales are 
presented in Table 3. The only significant difference was 
related to the psychostimulating activity where fluoxetine 
obtained better scores than milnacipran (P = 0.0008). 
Global assessments. The global results of the treatment by 
the investigator were rated as excellent in 19.3% of the 
cases, good in 24.7%, moderate in 27.9%, absent in 20.4% 
and negative in 7.5% with milnacipran and excellent in 
41.6% of cases, good in 19.1%, moderate in 14.6%, absent 
in 15.7% and negative in 9.0% with fluoxetine, indicating 
significantly better outcome with fluoxetine (Chi 2 = 5.57, 
df= 1, P--0 .02) .  The same ratings performed by the 
patient him/herself yielded 22.2% excellent, 15.6% good, 
27.8% moderate, 24.4% absent and 10.0% negative re- 
sults with milnacipran and 32.6% excellent, 20.2% good, 
16.9% moderate, 18.0% absent and 11.2% negative re- 
sults with fluoxetine (ChiZ = 1.9, df= 1, P = NS). The 
treatment was prolonged in 50.0% of patients treated with 
milnacipran and 63.3 % of the patients treated with fluoxe- 
tine (Chi z = 3.22, df = 1, P = 0.07). 
Side-effects 
The comparison of the frequency of side-effects recorded 
on the checklist in the two treatment groups is presented 
in Table 4. The only significant difference was related to 
symptoms of dizziness which were more frequent with 
milnacipran. It should be noted that all three side-effects 
considered as serious appeared in the fluoxetine group: 
generalized cutaneous rash with asthmatiform syndrome 
after 4 days of treatment leading to hospitalization, and 
two suicide attempts after, respectively, 15 and 30 days of 
treatment. During the study, mean weight (SD) decreased 
from 67.30 (13.1) kg to 67.09 (13.2) kg in the milnacipran 
group and from 67.59 (14.4) kg to 67.19 (13.8) kg in the 
fluoxetine group, without any significant difference be- 
tween the two treatments. 
Laboratory tests did not reveal significant changes 
during the treatment period. 
Associated lorazepam 
The number of patients taking occasionally lorazepam did 
not differ between the two groups: 98% with milnacipran 
versus 97% with fluoxetine at baseline, 64% versus 61% 
after 2 weeks, 63% versus 63% after 4 weeks, and 61% 
versus 60% after 6 weeks. 
Table 2. Comparison of efficacy on the 
CGI between milnacipran and fluoxetine 










wk 0 wk 2 wk 4 wk 6 F P 
4.30(0.62) 3.77(1.02) 3.17(1.33) 2.61(1.47) 
4.39(0.72) 3.45(1.31) 2.74(1.47) 2.00(1.68) 6.71 0.01 
- 2.23 (1.09) 1.80 (1.29) 1.37 (1.27) 
- 1.97(1.65) 1.37(1.37) 1.03(1.51) 3.20 0.08 
- 22,2(8.9) 17.4(10.1) 13.4(10.9) 
- 18.0(9.9) 12.8(8 .8)  9.2(10.6) 9.67 0.002 
Milnacipran Fluoxetine F P 
n = 97 n = 93 
Table 3. Clinical profile of 
antidepressant activity on 
visual analogue scales 
(mean and SD) 
Effect on depressed mood 52.0 (31.0) 59.8 (33.0) 2.59 NS 
Psychostimulating effect 37.6(29.4) 53.3(32.0) 11.58 0.0008 
Anxiolytic effect 34.5 (24.0) 40.0 (26.5) 2.14 NS 
Anticholinergic effects 7.9 (14.8) 6.8 (8.6) 0.38 NS 
Sedative effect 10.5 (16.0) 10.5 (15.0) 0.00 NS 
Hypotensive effect 6.6 (9.0) 7.1 (12.4) 0.tt NS 
Digestive effects 26.1 (28.5) 20.3 (24.0) 2.10 NS 
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Table 4. Comparison of the 
frequency of adverse events 
(%) 
Milnacipran group Fluoxetine group ;(2 p 
n = 97 n = 93 































weight gain, excessive 
weight loss, excessive 
others 
5.1 7.5 0.45 NS 
2.1 2.1 a NS 
13.4 10.7 0.31 NS 
0.0 1.1 a NS 
1.0 0.0 a NS 
0.0 2.1 a NS 
1.0 0.0 a NS 
6.2 5.4 0.06 NS 
1.0 0.0 a NS 
2.1 4.3 " NS 
0 .0  1.1 " NS 
7.2 3.2 " NS 
1.0 2.1 a NS 
11.3 7.5 0.80 NS 
~ 0  0 . 0  - NS 
7.2 6.4 0.04 NS 
1.0 1.1 a NS 
4.1 4.3 " NS 
19.6 17.2 1.07 NS 
5.1 4.3 a NS 
4.1 3.2 " NS 
6.2 4.3 a NS 
5.1 4.3 a NS 
0.0 0.0 ~ NS 
1.0 1.1 " NS 
9.3 6.4 0.52 NS 
13.4 3.2 a 0.01 
1.0 3.2 ~ NS 
7.2 7.5 0.00 NS 
6.2 8.6 0.41 NS 
"Fisher's exact test 
D i s c u s s i o n  
The results of the present study show a better antidepress- 
ant efficacy of fluoxetine at a daily dose of 20 mg as 
compared to milnacipran at a daily dose of 100 rag. In- 
deed, fluoxetine was found significantly superior to mil- 
nacipran on most  rating instruments: MADRS including 
five individual items and the number of responders, 
Hamil ton depression scale including ten individual items, 
CGI  of severity of illness and therapeutical index, and 
global rating by the investigator. These clear differences in 
efficacy favoring fluoxetine over milnacipran were rather 
surprising. Indeed, previous studies have demonstrated 
the antidepressant activity of milnacipran as better than 
placebo (Macher et al. 1989) and equivalent to reference 
tricyclics such as amitriptyline (Ansseau et al. 1989a, b, 
1991) or ctomipramine (Clerc et al. 1990). The only pub- 
lished placebo-controlled study tested a fixed dose of 
milnacipran 100 mg administered over a 5-week period in 
58 major depressive inpatients exhibiting a score of at least 
25 on the MADRS. Milnacipran was found more effective 
than placebo on all measures of depression already after 
2 weeks: MADRS (P = 0.003), Hamil ton depression scale 
P = 0.009), and Widlocher retardation scale (P = 0.04); 
moreover, the number of dropouts was higher in the 
placebo group (72%) than in the milnacipran group 
(24%). Therefore, this study showed that milnacipran 
100 mg daily was clearly effective among major  depressive 
inpatients. 
The therapeutic results of milnacipran in the present 
trial appear quite low in comparison with previous stud- 
ies: 40% of treatment responders as compared to 64% in 
the milnacipran data base (Solles et al. 1991). 
Three factors might explain the poor performance of 
milnaciPran in the present study. First, the 100-rag daily 
dose could have been selected below the optimal thera- 
peutic dose for this sample of psychiatric outpatients. 
Previous studies in psychiatric inpatients showed that ,  as 
compared to amitriptyline 150 mg/day, the latency of mil- 
nacipran 100 rag/day was somewhat longer, with differ- 
ences favoring amitriptyline after 2 weeks but disappear- 
ing 1 week later (Ansseau et al. 1989a). In contrast, mil- 
nacipran at a daily dose of 200 mg demonstrated similar 
rapidity of improvement  as amitriptyline 150mg/day 
(Ansseau et al. 1989b). Interestingly, the pooling of these 
two independent studies performed by the same group of 
investigators among psychiatric inpatients defined ac- 
cording to similar inclusion criteria revealed a clear dose- 
response relationship, with milnacipran 200mg/day  
being significantly more effective than the lower doses 
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(yon Frenckell et al. 1990). The 100-mg daily dose was 
selected for the present study on the rationale that de- 
pressive outpatients would need a lower dose than de- 
pressive inpatients (Ansseau 1992). Indeed, depressive out- 
patients are generally characterized by a lower level of 
severity than depressive inpatients. In a recent study com- 
paring the clinical characteristics of European depressive 
inpatients (n = 290) and outpatients (n = 183), von Fren- 
ckell et al. (1992) showed a significantly lower mean 17- 
item Hamilton depression score among outpatients (25.5 
versus 27.5, P = 0.001) with 6 items significantly higher 
among inpatients (suicide, initial insomnia, work and in- 
terest, retardation, psychic anxiety, and weight loss) and 
2 items significantly higher among outpatients (agitation 
and loss of libido). It should be acknowledged, however, 
that controlled studies confirming that depressive out- 
patients require smaller doses than inpatients suffering 
from the same disease are lacking in the literature. More- 
over, the severity of depressive symptomatology was very 
similar in the present trial and in previous trials among 
inpatients, with mean MADRS scores of, respectively, 33.5 
in the present study and of 37.1 and 40.1 among inpatients 
(Ansseau et al. 1989a, b), suggesting that our hypothesis 
was probably false. It remains obvious that the optimal 
dose of milnacipran still needs to be clearly defined and it 
would have been more appropriate to establish it in regu- 
lar dose-finding studies before comparing mitnacipran 
with other antidepressants. 
Second, milnacipran was given in one single daily dose 
in the present study whereas it was always administered in 
two divided daily doses in all previous trials. Since the 
plasma elimination half-life of milnacipran is about 7 h 
with only an inactive n-dealkylated metabolite (Puozzo et 
al. 1985), a single evening administration could lead to 
inadequate plasma levels. In contrast, the plasma half-life 
of fluoxetine is much longer (1-4 day) with norfluoxetine 
as an active metabolite with an even longer half-life (4-15 
days), justifying a single daily dose (Benfield et al. 1986). 
Support for the once a day administration as the major 
factor in the poor performance of milnacipran can be 
found in a comparison with a previous study of our group 
using the same 100-rag daily dose in two daily intakes 
(Ansseau et al. 1989a): the mean decrease in MADRS 
scores over a 4-week period was 59.8% as compared to 
30.2% in the present study. 
Third, to a lesser extent, the lower severity of initial 
depressive symptomatology in the milnacipran group, as 
shown on the Hamilton depression scale and on the speci- 
fic visual analogue scale, may have contributed to the 
limitation in treatment response. The higher number of 
passive aggressive personalities could also have played 
a role, even if the influence of axis II personality disorders 
on treatment response to antidepressants has never been 
specifically assessed previously. 
In the present study, the clinical profile of milnacipran 
and fluoxetine appeared somewhat different. On the glo- 
bal visual analogue scales, fluoxetine showed significantly 
more psychostimulating activity than milnacipran. This 
finding, which confirms a previous evaluation using the 
same parameters (Ansseau et al. 1988), might explain why 
fluoxetine is particularly suitable for depressive out- 
patients, in whom sedation should generally be avoided. 
In contrast, milnacipran seems characterized by a more 
"neutral" profile, as suggested in previous trials (Ansseau 
et al. 1989a, b, 1991; Macher et al. 1989; Clerc et al. 1990). 
The analysis of individual items of the MADRS and the 
Hamilton depression scale revealed, however, that the 
superiority of fluoxetine over milnacipran was also related 
to other depressive dimensions. Indeed, on the MADRS, 
they included apparent and expressed sadness, inner ten- 
sion, sleep reduction and pessimistic thoughts, and on the 
Hamilton depression scale, items related to the anxi- 
ety/somatization (psychic anxiety, somatic anxiety, gas- 
trointestinal symptoms), retardation (depressed mood, re- 
tardation, genital symptoms), and sleep disturbances 
(middle insomnia) factors, as defined by Guy (1976). 
Therefore, this study does not demonstrate that the pro- 
files of milnacipran and ftuoxetine really differ, but that 
milnacipran is globally less effective. 
In this study, the tolerance of milnacipran and fluoxe- 
tine was quite similar, with the exception of symptoms of 
dizziness which appeared more frequently with milnacip- 
ran. The majority of side-effects related to the gastrointes- 
tinal system. The incidence of nausea and vomiting with 
fluoxetine (respectively, 17.2% and 4.3%) was rather sim- 
ilar to previous reports (Benfield et al. 1986). In contrast, 
the incidence of nausea and vomiting observed with mit- 
nacipran (respectively, 19.6% and 5.1%) was between 
3 and 4 times higher than in previous studies with the 
same dose (Solles et al. 1991). This increased incidence is 
probably due to the administration of milnacipran in one 
single intake. 
In conclusions, several methodological pitfalls prevent 
us to rule out the possibility that a balanced noradrena- 
line/serotonin reuptake inhibitor is superior to a selective 
serotonin reuptake inhibitor. A response to the respective 
role of the dose and the schedule of administration in the 
antidepressant activity of milnacipran should come from 
further comparative trials. 
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